Bronchodilator Drugs - Norway | Statista Market Forecast

The Bronchodilator Drugs market in Norway is expected to see a significant increase in revenue in the coming years.
According to projections, the revenue is projected to reach US$92.03m in 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 2.76%.
This growth will result in a market volume of US$105.50m by 2029.
When comparing the global market, it is noteworthy that United States will generate the highest revenue.
In 2024, United States is expected to generate a staggering US$17.34bn in revenue.
In Norway, the market for bronchodilator drugs is dominated by innovative pharmaceutical companies offering advanced respiratory treatments.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are medications that help to relax the muscles in the airways, making it easier to breathe. In Norway, the market for bronchodilator drugs has been experiencing certain trends and developments.

Customer preferences: The preferences of customers in Norway for bronchodilator drugs are largely influenced by their healthcare system. The country has a universal healthcare system that is funded by taxes, which means that most of the cost of healthcare is covered by the government. This has led to a focus on cost-effectiveness in the healthcare system, with an emphasis on the use of generic medications.

Trends in the market: One of the major trends in the bronchodilator drugs market in Norway is the increasing use of inhalers. Inhalers are preferred over other forms of bronchodilator drugs because they are more targeted and have fewer side effects. Another trend is the increasing use of combination medications, which contain two or more bronchodilator drugs in a single inhaler. This is seen as a more convenient and cost-effective option for patients.

Local special circumstances: Norway has a high prevalence of asthma and other respiratory diseases, which has led to a high demand for bronchodilator drugs. Additionally, the country has a cold climate, which can exacerbate respiratory symptoms and increase the need for these medications.

Underlying macroeconomic factors: The Norwegian healthcare system is heavily regulated, with the government playing a large role in the pricing and reimbursement of medications. This has led to a focus on cost-effectiveness in the healthcare system, with a preference for generic medications and a push for more efficient use of resources. Additionally, the country has a high standard of living and a strong economy, which has allowed for investment in healthcare infrastructure and research.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.